Upcoming Events

I’ll be giving a talk at UC Davis from April 19-20th and UNC Chapel Hill from May 16-17th. If you’re in the area and would like to meet up, drop me a line

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology, Talks and Publications

April 8, 2007

08 Apr 2007

Write a chapter for my book on Advanced Topics in Biotechnology Business Development

Following up on the success of “Building Biotechnology” (www.BuildingBiotechnology.com), I’m in the late stages of assembling a more advanced follow-up book featuring articles from industry insiders with deep experience.

Join a dozen other industry insiders writing about topics in:

- Business Planning
- Funding
- Valuation
- Intellectual Property
- Licensing and technology transfer
- Public Relations

Further details available upon request. If you are interested, please respond using the contact form.

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology

April 3, 2007

03 Apr 2007

Drug Patent Expirations in April 2007

Courtesy of DrugPatentWatch.com:

Drug Patent Expirations in April 2007
*Drugs may be covered by more than one patent

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
AMBIEN	Sanofi Aventis Us	zolpidem tartrate	4,382,938	APR 21,2007
AMBIEN CR	Sanofi Aventis Us	zolpidem tartrate	4,382,938	APR 21,2007
BIDIL	Nitromed	hydralazine hydrochloride; isosorbide dinitrate	4,868,179	APR 22,2007
DEPAKOTE ER	Abbott	divalproex sodium	4,913,906	APR 03,2007
ELOCON	Schering	mometasone furoate	4,808,610	APR 02,2007
GLYNASE	Pharmacia And Upjohn	glyburide	4,916,163	APR 10,2007
INSPRA	Gd Searle Llc	eplerenone	4,559,332	APR 09,2007
NEXIUM	Astrazeneca	esomeprazole magnesium	4,738,974	APR 19,2007
PHOSLO	Fresenius Medcl	calcium acetate	4,870,105	APR 07,2007
PHOSLO GELCAPS	Fresenius Medcl	calcium acetate	4,870,105	APR 07,2007
VISUDYNE	Qlt	verteporfin	4,920,143	APR 24,2007
VOLTAREN	Novartis	diclofenac sodium	4,829,088	APR 14,2007

Courtesy of DrugPatentWatch.com

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology

April 1, 2007

01 Apr 2007

Genentech goes offshore

Genentech is investing $140mm in a new biologic manufacturing plant in Singapore. The first commercial-scale microbial fermentation plant in Singapore, and a significant International investment by US-based Genentech. This is the latest of a number of international manufacturing and R&D centers being located in Singapore, and is a sign of the growing trend of biotechnology operations being globally distributed in specialized centers with favorable economics, worker, or other resource availability.

In a related post, David Rosen reports that Indian trade possibilities boggle the mind while on an Illinois trade mission to India.